You just read:

European Hematology Association: First-in-Human CLL1-CD33 Compound CAR T Cells as a Two-Pronged Approach for the Treatment of Refractory Acute Myeloid Leukemia

News provided by

European Hematology Association

15 Jun, 2018, 07:30 BST